Current Report Filing (8-k)
April 01 2016 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): April 1, 2016
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Florida
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification
No.)
|
2 Snunit Street
|
|
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
20100
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including
area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.03 Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year
On April 1, 2016, Protalix BioTherapeutics, Inc. (the “Company”)
completed its previously announced reincorporation in the State of Delaware. Accordingly, the Company is now subject to the General
Corporation Laws of the State of Delaware. The reincorporation did not include any substantial changes to the rights, privileges
and powers of the company as it was incorporated in Florida. The Company continues to possess all of the assets it possessed prior
to the reincorporation, and continues to be subject to all of the same debts, liabilities and obligations. There was no change
of officers or directors as a result of the reincorporation. Each outstanding share of the Company’s common stock prior to
the reincorporation continues to be an outstanding share of the common stock of the Company, and each outstanding option or right
to acquire shares of our common stock prior to the reincorporation continues to be an option or right to acquire shares of the
Company’s common stock. The Company’s Certificate of Incorporation and Bylaws for the State of Delaware are attached
as exhibits to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
|
3.1
|
Certificate of Incorporation of the Company
|
|
3.2
|
Bylaws of the Company
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
Date:
April 1, 2016
|
By:
|
/s/
Yossi Maimon
|
|
|
Name:
|
Yossi Maimon
|
|
|
Title:
|
Vice President and Chief Financial Officer
|
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2024 to May 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From May 2023 to May 2024